335 related articles for article (PubMed ID: 18554313)
1. Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival.
Zaragoza O; Chrisman CJ; Castelli MV; Frases S; Cuenca-Estrella M; Rodríguez-Tudela JL; Casadevall A
Cell Microbiol; 2008 Oct; 10(10):2043-57. PubMed ID: 18554313
[TBL] [Abstract][Full Text] [Related]
2. Antifungal Peptide SP1 Damages Polysaccharide Capsule of Cryptococcus neoformans and Enhances Phagocytosis of Macrophages.
Liu Y; Zhang Y; Zhao X; Lu W; Zhong Y; Fu YV
Microbiol Spectr; 2023 Mar; 11(2):e0456222. PubMed ID: 36916981
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro.
Martinez LR; Casadevall A
Antimicrob Agents Chemother; 2006 Mar; 50(3):1021-33. PubMed ID: 16495265
[TBL] [Abstract][Full Text] [Related]
4. Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Ghaffar M; Orr C; Webb G
PLoS One; 2019; 14(12):e0225701. PubMed ID: 31800598
[TBL] [Abstract][Full Text] [Related]
5. Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival.
Geunes-Boyer S; Oliver TN; Janbon G; Lodge JK; Heitman J; Perfect JR; Wright JR
Infect Immun; 2009 Jul; 77(7):2783-94. PubMed ID: 19451250
[TBL] [Abstract][Full Text] [Related]
6. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.
Small JM; Mitchell TG
Infect Immun; 1989 Dec; 57(12):3751-6. PubMed ID: 2680980
[TBL] [Abstract][Full Text] [Related]
7. Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules.
Frases S; Pontes B; Nimrichter L; Viana NB; Rodrigues ML; Casadevall A
Proc Natl Acad Sci U S A; 2009 Jan; 106(4):1228-33. PubMed ID: 19164571
[TBL] [Abstract][Full Text] [Related]
8. Discordant regulation of phenoloxidase and capsular polysaccharide in Cryptococcus neoformans.
Jacobson ES; Compton GM
J Med Vet Mycol; 1996; 34(4):289-91. PubMed ID: 8873890
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans.
Levitz SM; DiBenedetto DJ
J Immunol; 1989 Jan; 142(2):659-65. PubMed ID: 2521352
[TBL] [Abstract][Full Text] [Related]
10. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations.
Nosanchuk JD; Cleare W; Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1999 Feb; 43(2):233-9. PubMed ID: 9925511
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang YY; Li L
Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131
[TBL] [Abstract][Full Text] [Related]
13. Phospholipids trigger Cryptococcus neoformans capsular enlargement during interactions with amoebae and macrophages.
Chrisman CJ; Albuquerque P; Guimaraes AJ; Nieves E; Casadevall A
PLoS Pathog; 2011 May; 7(5):e1002047. PubMed ID: 21637814
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
15. A putative P-type ATPase, Apt1, is involved in stress tolerance and virulence in Cryptococcus neoformans.
Hu G; Kronstad JW
Eukaryot Cell; 2010 Jan; 9(1):74-83. PubMed ID: 19949048
[TBL] [Abstract][Full Text] [Related]
16. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding.
Nosanchuk JD; Casadevall A
Infect Immun; 1997 May; 65(5):1836-41. PubMed ID: 9125569
[TBL] [Abstract][Full Text] [Related]
17. Capsules from pathogenic and non-pathogenic Cryptococcus spp. manifest significant differences in structure and ability to protect against phagocytic cells.
Araujo Gde S; Fonseca FL; Pontes B; Torres A; Cordero RJ; Zancopé-Oliveira RM; Casadevall A; Viana NB; Nimrichter L; Rodrigues ML; Garcia ES; Souza Wd; Frases S
PLoS One; 2012; 7(1):e29561. PubMed ID: 22253734
[TBL] [Abstract][Full Text] [Related]
18. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.
Paul S; Doering TL; Moye-Rowley WS
Fungal Genet Biol; 2015 Jan; 74():1-9. PubMed ID: 25445311
[TBL] [Abstract][Full Text] [Related]
19. Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.
Zaragoza O; Mihu C; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2005 Oct; 49(10):4358-61. PubMed ID: 16189121
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst.
Sangalli-Leite F; Scorzoni L; Mesa-Arango AC; Casas C; Herrero E; Gianinni MJ; Rodríguez-Tudela JL; Cuenca-Estrella M; Zaragoza O
Microbes Infect; 2011 May; 13(5):457-67. PubMed ID: 21310262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
